ASSESSMENT OF POTENTIAL COCAINE TREATMENT MODIFICATIONS IN NON-HUMAN 
PRIMATES   

Release Date:  August 21, 2002

NOTICE:  NOT-DA-03-022

RFP AVAILABLE:	N01DA-38831

National Institute on Drug Abuse (NIDA)
 
The National Institute on Drug Abuse (NIDA) is soliciting proposals 
from qualified businesses to perform non-human primate pharmacology 
studies of potential pharmacotherapies for cocaine dependence by 
evaluating compounds in drug discrimination and self-administration 
paradigms in non-human primates. Specifically, the contractor tests 
compounds for: (1) potency in substituting or blocking the 
discriminative stimulus effects of cocaine and (2) potency for altering 
cocaine self-administration or the propensity for self-administration 
in non-human primates. The Contractor is blinded to the identity of 
proprietary test compounds, the compounds are evaluated in established 
assays, and the resulting data is utilized by the NIDA's Division of 
Treatment Research and Development. In order to handle substances under 
the Controlled Substances Act of 1970, it is mandatory that offerors 
possess a Drug Enforcement Administration (DEA) research registration 
for Schedules II through V and demonstrate the capability to obtain a 
DEA registration for Schedule I Controlled Substances. NIDA anticipates 
one award for a five-year incrementally funded combination 
completion/term-type contract for this procurement. Additional quantity 
options are included. RFP No. N01DA-3-8831 will be available 
electronically on or about September 3, 2002. You can access the RFP 
through the FedBizOpps (URL: http://www.fedbizopps.gov) or through the 
NIDA website (URL: http://www.nida.nih.gov/RFP/RFPList.html). Please note 
that NIDA uses the streamlined RFP format which includes only the work 
statement, deliverables, reporting requirements, special requirements, 
mandatory qualifications, technical evaluation criteria, and other 
necessary proposal preparation instructions. All information required 
for the submission of a proposal is contained in or accessible through 
the streamlined RFP package. Response to the RFP will be due on or 
about November 4, 2002. NIDA will consider proposals submitted by any 
responsible offeror. This advertisement does not commit the government 
to award a contract. See Note 26. 
 
Point of Contact:
 
Teneshia G. Alston, Contract Specialist
National Institute on Drug Abuse, NIH
Contracts Management Branch, OPRM
6001 Executive Blvd., Rm. 3105 (NSC)
Bethesda, MD 20892-9543
E-mail address:  talston@mail.nih.gov
TEL:  (301) 435-1364
FAX:  (301) 443-7595

Return to Volume Index

Return to NIH Guide Main Index

	Office of Extramural Research (OER)			National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892			Department of Health and Human Services (HHS)
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.